8-K: Charles River Labs Q1 2026 Earnings: Revenue Up Slightly, EPS Down

Charles River Laboratories reported Q1 2026 results with revenue increasing 1.2% year-over-year to $995.8 million, while GAAP loss per share was $(0.30) and non-GAAP EPS was $2.06, down from the prior year.

Summary

• Charles River Laboratories announced its first-quarter 2026 financial results, reporting total revenue of $995.8 million, a 1.2% increase compared to $984.2 million in the first quarter of 2025.
• The company reported a GAAP net loss of $(14.8) million, or $(0.30) per diluted share, a significant decrease from a net income of $25.5 million, or $0.50 per diluted share, in Q1 2025.
• Non-GAAP net income was $101.7 million, a 14.6% decrease from $119.1 million in Q1 2025, with non-GAAP diluted earnings per share at $2.06, down 12.0% from $2.34 in the prior year.
• The company completed the divestiture of its CDMO and Cell Solutions businesses on May 6, 2026, and expects to complete the sale of certain European Discovery Services sites in May 2026.
• Charles River reaffirmed its 2026 guidance for organic revenue and non-GAAP earnings per share but reduced its reported revenue outlook by approximately 50 basis points due to foreign exchange rate changes.
• The company repurchased $200 million of common stock in the first quarter of 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment, as revenue growth is minimal, and both GAAP and non-GAAP earnings per share have declined year-over-year, despite meeting financial targets and reaffirming guidance.

Positives

• Total revenue increased by 1.2% to $995.8 million in Q1 2026.
• The Manufacturing Solutions segment saw organic revenue increase by 2.9%.
• GAAP operating margin improved to 12.0% in Q1 2026 from 7.6% in Q1 2025, primarily due to lower accelerated amortization expense.
• The company reaffirmed its 2026 guidance for organic revenue and non-GAAP earnings per share.
• Repurchased $200 million of common stock in Q1 2026.
• The DSA segment reported solid bookings in the first quarter.
• The company completed the divestiture of CDMO and Cell Solutions businesses, allowing for a refocus on core competencies.

Negatives

• GAAP net loss of $(14.8) million in Q1 2026, compared to a net income of $25.5 million in Q1 2025.
• Non-GAAP net income decreased by 14.6% to $101.7 million in Q1 2026.
• Non-GAAP diluted earnings per share decreased by 12.0% to $2.06 in Q1 2026.
• Organic revenue declined by 1.5% overall, with the Research Models and Services (RMS) segment down 5.5% and the Discovery and Safety Assessment (DSA) segment down 1.4%.
• Non-GAAP operating margin decreased to 16.3% from 19.1% in Q1 2025.
• The GAAP net loss was significantly impacted by an $118.0 million loss on assets held for sale related to the CDMO and Cell Solutions divestiture.

Risks

• Impact of NHP supply constraints.
• Changes and uncertainties in the global economy and financial markets, including disruptions from geopolitical conflicts.
• Ability to successfully integrate acquired businesses and risks associated with acquired businesses.
• Negative trends in research and development spending or the level of outsourced services by clients.
• Ability to convert backlog to revenue.
• Demand and booking trends.
• Changes in tax regulations and laws.
• Fluctuations in interest rates and foreign currency exchange rates.

Future Outlook

Charles River Laboratories reaffirms its 2026 guidance for organic revenue and non-GAAP earnings per share. However, the company is reducing its reported revenue outlook by approximately 50 basis points due to recent changes in foreign exchange rate assumptions. The GAAP earnings per share guidance has been updated to reflect the impact of divestitures.

Management Comments

• "We are pleased to deliver on our first-quarter financial targets, and remain well positioned to generate improving results over the course of the year."
• "Our confidence is supported by a DSA demand environment that is tracking to our expectations, resulting in solid bookings in the first quarter, as well as the successful execution of our strategy."
• "As we look to the future, our focus remains on enhancing our clients experience, strengthening our world-class scientific portfolio, achieving our financial and operational goals, and increasing long-term shareholder value."
• "I am energized to lead this great company into its next chapter of growth and am confident in the path we are taking to create the future for Charles River."

Industry Context

StockSavvy.ai notes that Charles River Laboratories' Q1 2026 results reflect ongoing industry trends in the life sciences services sector, including the impact of divestitures to focus on core competencies and the challenges of organic revenue growth in certain segments like Research Models and Services (RMS) and Discovery and Safety Assessment (DSA). The reaffirmation of guidance despite a slight reduction in reported revenue outlook due to FX suggests resilience in core operations and demand for their services.

Legal Proceedings

• The company mentions "third-party legal costs related to a non-human primate (NHP) supply matter" in the DSA segment's GAAP operating margin discussion, implying past or ongoing legal matters.

Stakeholder Impact

• Shareholders: The company repurchased $200 million of common stock, which can increase shareholder value through reduced share count. However, the decrease in EPS may be a concern.
• Employees: The report mentions higher stock-based compensation expense related to executive transition, potentially impacting employee morale or compensation structures.
• Clients: The company aims to enhance client experience and strengthen its portfolio, suggesting a focus on maintaining and improving client relationships.
• Suppliers: No specific impact mentioned, but operational changes and divestitures could indirectly affect supplier relationships.

Next Steps

• Complete the sale of certain European Discovery Services sites in May 2026.
• Continue to focus on enhancing client experience, strengthening the scientific portfolio, and achieving financial and operational goals.
• Evolve and lead the industry through modernization and a refreshed strategic focus.
• Enable the company to realize its full potential and ensure future success.

Key Dates

Recommendation

The company met its Q1 financial targets and reaffirmed full-year guidance, which is positive. However, the reported GAAP net loss and the decline in non-GAAP EPS year-over-year, coupled with modest revenue growth and organic revenue decline in key segments, suggest a cautious outlook. The strategic divestitures are a positive step towards focus, but the immediate financial performance warrants a 'hold' recommendation until clearer signs of sustained growth and improved profitability emerge.

Keywords

Charles River Laboratories, Q1 2026 Earnings, Revenue, GAAP Loss, Non-GAAP EPS, Divestiture, Manufacturing Solutions, Research Models and Services